Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities

BACKGROUND: Elderly patients (≥65 yr) with advanced prostate cancer and cardiovascular disease (CVD) conditions are often excluded from clinical trials of abiraterone acetate (AA) or enzalutamide (ENZ). Consequently, little is known about the effects of these medications on these vulnerable patients...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Eur Urol
Autores principales: Lu-Yao, Grace, Nikita, Nikita, Keith, Scott W., Nightingale, Ginah, Gandhi, Krupa, Hegarty, Sarah E., Rebbeck, Timothy R., Chapman, Andrew, Kantoff, Philip W., Cullen, Jennifer, Gomella, Leonard, Kelly, William Kevin
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6980462/
https://ncbi.nlm.nih.gov/pubmed/31420248
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2019.07.031
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares